Bard Associates’s Biofrontera BFRI Stock Holding History

Bard Associates’s Portfolio BFRI Stock Details BFRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-9,560	Closed	-$99.4K	–	188
2023 Q2	$99.4K	Sell	9,560 -350	-4%	-$3.72K	0.04%	170
2023 Q1	$121K	Hold	9,910	–	–	0.05%	172
2022 Q4	$182K	Sell	9,910 -2,754	-22%	-$56.2K	0.08%	164
2022 Q3	$266K	Sell	12,664 -300	-2%	-$8.2K	0.12%	139
2022 Q2	$482K	Buy	12,964 +660	+5%	+$40.1K	0.21%	110
2022 Q1	$819K	Sell	12,304 -4,847	-28%	-$351K	0.29%	105
2021 Q4	$2.58M	Buy	+17,151	New	+$1.88M	0.85%	44

Other funds holding BFRI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

CSPIA

Cary Street Partners Investment Advisory Richmond, Virginia $494M AUM 27.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bard Associates's BFRI Position: Q3 2023 in Review

Bard Associates sold out of Biofrontera (BFRI) in Q3 2023, closing a stake of 9,560 shares — an estimated $99.4K sold.

Bard Associates first reported a position in BFRI in Q4 2021 and held it in 7 quarters. The position peaked at $2.58M in Q4 2021. 8 funds tracked by Wall St. Rank hold BFRI as of Q3 2023.

Bard Associates reported no remaining Biofrontera position as of Q3 2023 after selling out during the quarter.
Bard Associates sold 9,560 Biofrontera shares in Q3 2023, an estimated $99.4K.
Bard Associates first reported a position in Biofrontera in Q4 2021 and held it in 7 quarters.
Bard Associates's Biofrontera position peaked at $2.58M in Q4 2021.
8 funds tracked by Wall St. Rank held Biofrontera as of Q3 2023.

Based on Bard Associates's 13F filing for Q3 2023, filed 13 Nov 2023.